Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Endocrinología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight
INTERVENTIONAL
Inicio: 25 de abr de 2025
ID: NCT06914895
Terminado
Fase 3
ClinicalTrials.gov
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
INTERVENTIONAL
Inicio: 16 de feb de 2018
ID: NCT03426345
Completado
Fase 3
ClinicalTrials.gov
A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)
INTERVENTIONAL
Inicio: 1 de ene de 2005
ID: NCT00116831
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00642278
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00395512
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de mar de 2009
ID: NCT00856284
Completado
Fase 3
ClinicalTrials.gov
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin
INTERVENTIONAL
Inicio: 1 de oct de 2009
ID: NCT00984867
Completado
Fase 3
ClinicalTrials.gov
Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.
INTERVENTIONAL
Inicio: 1 de may de 2006
ID: NCT00331851
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
INTERVENTIONAL
Inicio: 7 de dic de 2018
ID: NCT03701334
Completado
ClinicalTrials.gov
SELECT-LIFE (SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication)
OBSERVATIONAL
Inicio: 1 de sept de 2023
ID: NCT04972721
Terminado
Fase 3
ClinicalTrials.gov
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
INTERVENTIONAL
Inicio: 10 de may de 2021
ID: NCT04752332
Completado
Fase 3
ClinicalTrials.gov
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
INTERVENTIONAL
Inicio: 11 de oct de 2017
ID: NCT03199053
Completado
ClinicalTrials.gov
Continuation of Follow-up for Patients Who Were Previously Enrolled in the Clinical Study: "Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity - (Protocol 11-03)."
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01429194
Reclutando
Fase 3
ClinicalTrials.gov
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
INTERVENTIONAL
Inicio: 30 de abr de 2025
ID: NCT06952530
Terminado
Fase 4
ClinicalTrials.gov
A Pharmacy Based Open Study to Evaluate Whether Pack Size Affects Compliance for Subjects Diagnosed With Diabetes Type II Who Are Established on Metformin Treatment
INTERVENTIONAL
Inicio: 1 de may de 2013
ID: NCT01817777
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
INTERVENTIONAL
Inicio: 12 de ago de 2022
ID: NCT05463744
Terminado
Fase 2
ClinicalTrials.gov
A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease
INTERVENTIONAL
Inicio: 6 de mar de 2014
ID: NCT01915303
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
INTERVENTIONAL
Inicio: 16 de oct de 2025
ID: NCT07215559
Activo, no recluta
Fase 3
ClinicalTrials.gov
MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
INTERVENTIONAL
Inicio: 22 de nov de 2024
ID: NCT06672237
Completado
Fase 3
ClinicalTrials.gov
Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease
INTERVENTIONAL
Inicio: 17 de jun de 2019
ID: NCT03819153
Anterior
1
...
13
14
15
...
434
Siguiente
Filtros